Amid growing healthcare awareness in the region, lung cancer screening providers in the region has ample opportunities. These include collaborating with regional hospitals and clinics through which they can offer accessible lung cancer screening and leveraging telemedicine for remote areas. This approach not only detects lung cancer early but also improves patient outcomes, filling a crucial gap in the region’s healthcare. By aligning with the rising demand for preventive care, these providers can establish a foothold in a promising market, ultimately contributing to enhanced public health and well-being across the region.
The Middle East & Africa lung cancer screening market has been segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. Saudi Arabia is expected to account for the largest market share and is expected to develop moderately in the Middle East & Africa. Factors that are driving the Middle East & Africa lung cancer screening market growth are increasing awareness of screening & diagnosis and growing initiatives by government and clinical & research institute. Iran, Iraq, Turkey, Kuwait, Qatar, Kenya, and Israel are among the major contributors to the lung cancer screening market in the Rest of Middle East & Africa. According to a report published in NCBI, in Qatar, lung cancer is a prevalent health condition, which can be attributed to the rising use of tobacco. The survival rate among lung cancer patients in Qatar is lower than the global average. Further, various factors such as distant metastasis, smoking status, and treatment history are associated with lung cancer survival in Qatar. Due to low survival rates, the Qatari government highly recommends screening for lung cancer. The Turkish Society of Lung Cancer had established a “Tobacco Control Committee” to promote tobacco control throughout Turkey and make the public aware of lung cancer as well as the need for screening. These factors propel the demand for lung cancer screening procedures in the Rest of the Middle East & Africa
Middle East & Africa Lung Cancer Screening Market Segmentation
The Middle East & Africa lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.
Based on cancer type, the Middle East & Africa lung cancer screening market is segmented into non–small cell lung cancer (NSCLC), and small cell lung cancer. The non–small cell lung cancer (NSCLC) segment held a larger share of the Middle East & Africa lung cancer screening market in 2022.
Based on technology, the Middle East & Africa lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Chest X-ray segment held the largest share of the Middle East & Africa lung cancer screening market in 2022.
Based on age group, the Middle East & Africa lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the Middle East & Africa lung cancer screening market in 2022.
Based on end user, the Middle East & Africa lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the Middle East & Africa lung cancer screening market in 2022.
Based on country, the Middle East & Africa lung cancer screening market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. The Rest of Middle East & Africa dominated the Middle East & Africa lung cancer screening market in 2022.
Siemens AG, Koninklijke Philips NV, Canon Inc, Medtronic, GE HealthCare, and Nuance Communications Inc are some of the leading companies operating in the Middle East & Africa lung cancer screening market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 17.52 Million |
| Market Size by 2030 | US$ 30.11 Million |
| CAGR (2022 - 2030) | 7.0% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Cancer Type
|
| Regions and Countries Covered |
Middle East and Africa
|
| Market leaders and key company profiles |
|
The Middle East & Africa Lung Cancer Screening Market is valued at US$ 17.52 Million in 2022, it is projected to reach US$ 30.11 Million by 2030.
As per our report Middle East & Africa Lung Cancer Screening Market, the market size is valued at US$ 17.52 Million in 2022, projecting it to reach US$ 30.11 Million by 2030. This translates to a CAGR of approximately 7.0% during the forecast period.
The Middle East & Africa Lung Cancer Screening Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Lung Cancer Screening Market report:
The Middle East & Africa Lung Cancer Screening Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East & Africa Lung Cancer Screening Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East & Africa Lung Cancer Screening Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East & Africa Lung Cancer Screening Market
